Healthcare U.K. Community

A case for buying shares in AIM: TSTL Tristel currently rests on a combination of recent share-price weakness and improving business fundamentals. The share price has fallen to around GBX 385–390p in mid-March 2026 after trading above GBX 420–430p earlier in the year, leaving it noticeably below its recent range and close to the middle of its 52-week band of roughly GBX 260p–445p.Read more

Key Takeaways Expansion into the Australian market aims to boost revenue and EBITDA through strategic acquisitions and synergies. Improvement in customer engagement and service delivery is expected to enhance client retention and increase sales.Read more

ANGLE is betting that more cancer testing shifts to simple blood draws, and it’s trying to stand out with a tool used in drug trials that could expand into wider clinical use. The upside hinges on turning a handful of big pharma partnerships into repeat business, but slow hospital adoption and funding swings could keep results lumpy.Read more

Creo Medical Group targets a growing shift toward less invasive treatment, with new devices and partnerships that could help it win more hospitals and expand overseas. But its sales have been uneven and costs stay high, so the next phase depends on turning product launches and cost cuts into reliable growth.Read more

Spire’s UK private hospitals could get a lift as long NHS waits push more people to pay for treatment, while new technology and streamlined back-office systems aim to make care faster and less costly to deliver. The catch is that insurer referrals, staff costs, NHS funding choices, and tougher competition could quickly squeeze volumes and profits.Read more

Integrated Diagnostics Holdings is pushing into Saudi Arabia while adding more locations in Egypt, aiming to turn strong demand for medical tests into steadier growth and better profits. The big question is whether it can expand smoothly despite inflation, currency swings, and political and economic instability across key markets.Read more

CVS Group runs veterinary clinics and related pet services, but rising staff costs, tougher rules, and new digital competitors could make it harder to keep growing the way it has. See why some believe the business may face pressure from both regulators and changing customer habits, even as expansion and new services offer a path forward.Read more

Key Takeaways Rapid innovation in robotics and implants, plus strong platforms in sports medicine and wound care, drive market share gains and recurring revenue growth. Operational improvements and global diversification support higher margins, cash flow, and flexible investment for sustained earnings and shareholder returns.Read more

Catalysts About Kooth Kooth provides digital mental health platforms for young people, working with public sector and state funders in the U.K. and U.S. What are the underlying business or industry changes driving this perspective? Growing recognition by governments that traditional crisis-led mental health systems are too expensive and cannot meet demand, together with Kooth’s role as a digital, early intervention provider for 20 million people globally, positions the company to capture a larger share of public funding over time, which directly supports revenue growth.Read more